4S neuroblastoma: The long‐term outcome

Levitt, Gill; Platt, KA; Byrne, Roisin; Sebire, Neil J.; Owens, Cormac

doi:10.1002/pbc.20067

Cited by 24 publications

(17 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…As reported in literature, very young patients (diagnosed before 2 months old) had the worst prognosis. [5][6][7][8] The survival rate was found significantly lower in these patients when compared with older patients aged 3 to 12 months old. All except 2 patients had CT, but CT alone was not effective in all.…”

Section: Discussionmentioning

confidence: 69%

Neuroblastoma in Turkish Children

Aydn

Kutluk²,

Yalçn³

et al. 2009

Journal of Pediatric Hematology/Oncology

View full text Add to dashboard Cite

The survival rates in children with local disease are comparable with the results of developed countries; however, the results in children with advanced disease are still not satisfactory. To improve the outcome, especially in children with advanced disease, more effective chemotherapy regimens and molecular therapies should be investigated. Sharing the knowledge and capacity building to improve the treatment results in NBL are also critical for developing countries.

show abstract

Section: Discussionmentioning

confidence: 69%

Neuroblastoma in Turkish Children

Aydn

Kutluk²,

Yalçn³

et al. 2009

Journal of Pediatric Hematology/Oncology

View full text Add to dashboard Cite

show abstract

“…Normalization of liver architecture has been reported by Levitt et al. and French et al., who describe liver architecture normalization in 42% and 48% of 28 and 15 patients, respectively . One study described liver size normalization in < 12 months in two patients .…”

Section: Discussionmentioning

confidence: 97%

“…Catecholamine excretion and liver size normalization occurred in 83% and 91% of the patients after a median of two in 42% and 48% of 28 and 15 patients, respectively. 15,16 One study described liver size normalization in < 12 months in two patients. 17 Early expansion of liver metastases caused respiratory distress requir- Antitumor treatment is given in patients with type A progression in an attempt to induce tumor regression to prevent clinical complications of organ compression.…”

Section: Discussionmentioning

confidence: 99%

Neuroblastoma stage 4S: Tumor regression rate and risk factors of progressive disease

Tas

Nagtegaal

Kraal

et al. 2019

Pediatric Blood & Cancer

View full text Add to dashboard Cite

Background The clinical course of neuroblastoma stage 4S or MS is characterized by a high rate of spontaneous tumor regression and favorable outcome. However, the clinical course and rate of the regression are poorly understood. Methods A retrospective cohort study was performed, including all patients with stage 4S neuroblastoma without MYCN amplification, from two Dutch centers between 1972 and 2012. We investigated the clinical characteristics, the biochemical activity reflected in urinary catecholamine excretion, and radiological imaging to describe the kinetics of tumor regression, therapy response and outcome. Results The cohort of 31 patients reached a 10‐year overall survival of 84% ± 7% (median follow‐up 16 years; range, 3.3‐39). During the regressive phase, liver size normalized in 91% of the patients and catecholamine excretion in 83%, both after a median of two months (liver size: range, 0‐131; catecholamines: range, 0‐158). The primary tumors completely regressed in 69% after 13 months (range, 6‐73), and the liver architecture normalized in 52% after 15 months (range, 5‐131). Antitumor treatment was given in 52% of the patients. Interestingly, regression rates were similar for treated and untreated patients. Four of seven patients < 4 weeks old died of rapid liver expansion and organ compression. Three patients progressed to stage 4, 3 to 13 months after diagnosis; all had persistently elevated catecholamines. Conclusion Patients < 4 weeks old with neuroblastoma stage 4S are at risk of fatal outcome caused by progression of liver metastases. In other patients, tumor regression is characterized by a rapid biochemical normalization that precedes radiological regression.

show abstract

“…Children less than 1 year of age with stages 3 and 4 tumours have 1-year event-free survival rates of 80%–90% and 60%–75%, respectively. Children older than 1 year with INSS stages 3 and 4 tumours have 3-year event-free survival rates of 50% and 15%, respectively [2, 6, 14]. …”

Section: Clinical Stagingmentioning

confidence: 99%